Rhea-AI Summary
Rafarma Pharmaceuticals, OTC: RAFA, has announced the approval of Ilya Shpurov acquiring the majority of Preferred B shares, granting him voting control of the company. This move is part of Rafarma's acquisition by R. & D. BIOCOGENCY LABORATORIES Group. Significantly, the issuance of these restricted preferred shares does not dilute common shares. CEO Vladimir Dolgolenko expressed optimism about Shpurov's leadership and the increased value for Rafarma stemming from this transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
FAQ
What is the current stock price of RAFARMA PHARMA (WY) (RAFA)?
RAFARMA PHARMA (WY) (RAFA) last closed at $0.014.
What is the market cap of RAFARMA PHARMA (WY) (RAFA)?
The market cap of RAFARMA PHARMA (WY) (RAFA) is approximately $8.6M.